

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Robert Lookstein

Page 1/4

Tuesday, January 26, 2021

MAIN ARENA 1

- 11:45 – 12:10** **Pioneering approaches and new data: focus on venous and AV-shunt treatment**
MODERATOR:
Marianne Brodmann
Michael Lichtenberg
PANEL:
Robert Shahverdyan
Tobias Steinke
- 11:45 – 11:50 FIRST TIME DATA RELEASE: The IN.PACT AV access trial: subset outcomes through 12 month
Andrew Holden
- 11:50 – 11:55 The IN.PACT AV access trial – economic outcomes
Robert Lookstein
- 11:55 – 12:00 VIVO clinical study: Zilver Vena stent – 12 month results
Lawrence Hofmann
- 12:00 – 12:05 Data from the ABRE study: clinical patient presentations in iliofemoral venous outflow obstruction –
aDVT, PTS, NIVL
Erin Murphy
- 12:05 – 12:10 FIRST TIME DATA RELEASE: Retrospective comparison of surgical AV access fistula creation vs. pAVF
creation
Robert Shahverdyan

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

The logo for the Leipzig Interventional Course (LINC) features the letters 'L I N C' in a bold, blue, sans-serif font. The letters are arranged horizontally with significant spacing between them. Behind the letters is a large, abstract, blue brushstroke graphic that curves from the bottom left towards the top right, partially overlapping the letters.

Robert Lookstein

Page 2/4

Wednesday, January 27, 2021

MAIN ARENA 1

- 19:00 – 20:20** **VIVA/LINC – Joint session on the current status and future of drug-eluting therapies**
MODERATOR:
Dierk Scheinert
Peter Schneider
PANEL:
Andrew Holden
Marianne Brodmann
Robert Lookstein
- 19:00 – 19:03 Introduction by the moderators
Dierk Scheinert
Peter Schneider
- 19:03 – 19:08 Insights on paclitaxel safety from the femoral-popliteal RCTs
Peter Schneider
- 19:08 – 19:13 Insights on paclitaxel safety from femoral-popliteal real-world data
Eric Secemsky
- 19:13 – 19:21 New insights from the interim safety analysis of the SWEDEPAD study
Joakim Nordanstig
- 19:21 – 19:26 How does the Voyager data help us understand the risks of paclitaxel?
Marc Bonaca
- 19:26 – 19:31 Paclitaxel safety in patients with CLTI
Marianne Brodmann
- 19:31 – 19:36 Newly FDA-approved paclitaxel devices for lower extremity and dialysis and the regulatory implications
Robert Lookstein
- 19:36 – 19:41 New data on paclitaxel in the next couple of years; what should we expect?
Eva Freisinger
- 19:41 – 19:49 Panel discussion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Robert Lookstein

Page 3/4

Wednesday, January 27, 2021

- | | |
|---------------|---|
| 19:49 – 19:54 | Paclitaxel vs. limus agents. Mechanism of action, what are the challenges to move beyond paclitaxel?
Sahil Parikh |
| 19:54 – 19:59 | Previous experience with limus compounds in the non-coronary arteries; lessons learned
Thomas Zeller |
| 19:59 – 20:04 | New limus delivering devices for above and below knee occlusive disease; when to expect results?
Andrew Holden |
| 20:04 – 20:14 | Blue horizon keynote speech: Potential for drug delivery in the treatment of lower extremity occlusive disease: what will the practice look like in 5 years?
Dierk Scheinert |
| 20:14 – 20:20 | Panel discussion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Robert Lookstein

Page 4/4

Friday, January 29, 2021

MAIN ARENA 1

14:50 – 15:35

DEEP DIVE SESSION: Management of AV-access obstructions

MODERATOR:

Robert Lookstein

Jos van den Berg

PANEL:

Jeffrey Hull

Robert Jones

Henrik Sillesen

14:50 – 14:55

Restoring arteriovenous access: pilot study using a scoring balloon in 50 patients

John Ross

14:55 – 15:00

Ultrasound guided PTA of AV fistula – improve care for your patients and increase capacity of your angiosuite

Henrik Sillesen

15:00 – 15:05

The IN.PACT AV access trial – the data so far

Robert Lookstein

15:05 – 15:10

Safety and efficacy of drug eluting balloon angioplasty of dialysis fistula: 12 month outcomes from a randomized clinical trial with Passeo-18 Lux

Éric Thérasse

15:10 – 15:15

1 year results from the MAGicTouch intervention leap for dialysis access – the MATILDA trial

Tjun Tang

15:15 – 15:20

The role of balloon angioplasty and stent-grafts in my treatment algorithm for hemodialysis access salvage

Daniel Patel

15:20 – 15:25

Treating AVF lesions in the cephalic arch: cases and context

Jeffrey Hull

15:25 – 15:30

Management of cephalic arch stenosis: have stent-grafts become the gold standard?

Robert Jones

15:30 – 15:35

Maturation for hemodialysis in the Ellipsys registry

Jeffrey Hull

We are asking all faculty members to strictly respect the given time limits.